Your session is about to expire
← Back to Search
pembrolizumab for Endometrial Cancer
Study Summary
This trial is testing a new cancer treatment combination in women with endometrial cancer or other solid tumors.
- Recurrent Endometrial Cancer
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1274 Patients • NCT02220894Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the upper limit of participants taking part in this clinical experiment?
"Confirmative. According to the records published on clinicaltrials.gov, this investigation is currently looking for enrollees and was first posted September 8th 2022 with a subsequent edit occurring on September 12th 2022. A total of 30 participants are required from one medical centre."
Has pembrolizumab earned recognition from the Food and Drug Administration?
"While pembrolizumab has been proven to be reasonably safe, its efficacy is yet to be confirmed. As such, this drug's safety was rated at 2 on a scale of 1-3."
Is recruitment currently open for this experiment?
"Yes, clinicaltrials.gov details suggest this medical research is actively seeking participants for enrollment. It was initially posted on September 8th 2022 and last updated on the 12th of that month. 30 patients are required at one site for completion of the trial."
Share this study with friends
Copy Link
Messenger